



\$176

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Uckun et al.	Examiner:	Howard V. Owens, Jr.
Serial No.:	10/726,073	Group Art Unit:	1623
Filed:	December 1, 2003	Docket:	12152.15USC6
Customer No.:	23552	Confirmation No.:	2559
Title:	Aryl Phosphate Derivatives of d4T having Anti-HIV Activity		

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: , Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 on June 30, 2005.

By: Patricia L. Lammone  
Name:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing.
- ☒ Supplemental Information Disclosure Statement, Form 1449, 24 References.
- ☒ Check in the amount of \$180.00 for submission of supplement IDS.
- ☒ Return postcard.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.  
P.O. Box 2903  
Minneapolis, MN 55402-0903  
612.332.5300

By: Anne M. Murphy  
Name: Anne M. Murphy  
Reg. No.: 54,327  
AMM:pll



10/726,073

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Uckun et al.	Examiner:	Howard V. Owens, Jr.
Serial No.:	10/726,073	Group Art Unit:	1623
Filed:	December 1, 2003	Docket No.:	12152.15USC6
Customer No.:	23552	Confirmation No.:	2559
Title:	Aryl Phosphate Derivatives of d4T having Anti-HIV Activity		

**CERTIFICATE UNDER 37 CFR 1.8:**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2005

By: *Patricia L. Lavinion*  
Name:**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

07/08/2005 SHASSEN1 00000006 10726073

01 FC:1806

180.00 OP

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Enclosed is a check in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

Because this application was filed after June 30, 2003, copies have been provided only for the foreign patent documents or "Other documents" listed on the enclosed Form 1449 that have not previously been cited by or submitted to the U.S. Patent and Trademark Office in parent application, U.S. Serial No. 09/548,494, filed on April 13, 2000.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to

establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,  
MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Date: June 30, 2005

By: Anne M. Murphy  
Name: Anne M. Murphy  
Reg. No.: 54,327  
AMM:pll

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.15USC6	Application Number: 10/726,073
	Applicant: Ucken et al.	Confirmation No.: 2559
	Filing Date: December 1, 2003	Group Art Unit:

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,455,513 B1	09/24/2002	McGuigan et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Abraham T. et al., "A Phosphoramidite-Based Synthesis of Phosphoramidate Amino Acid Diesters of Antiviral Nucleosides", Nucleosides & Nucleotides, Vol. 13(9), pp. 1891-1903 (1994).
	Aquaro, S. et al. "Activities of Masked 2', 3'-Dideoxynucleoside Monophosphate Derivatives against Human Immunodeficiency Virus in Resting Macrophages", Antimicrobial Agents and Chemotherapy, Vol. 44, No. 1, pp. 173-177 (Jan. 2000).
	Balzarini, J. et al. "Mechanism of Anti-HIV Action of Masked Alaninyl d4T-MP Derivatives", Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 7295-7299 (July 1996).
	Cahard, D. et al., "Aryloxy Phosphoramidate Triesters as Pro-Tides", Mini-Reviews in Medicinal Chemistry, Vol. 4, pp. 371-381 (2004).
	Curley, D. et al. "Synthesis and Anti-HIV Evaluation of Some Phosphoramidate Derivatives of AZT: Studies on the Effect of Chain Elongation of Biological Activity", Vol. 14 No. 6., Antiviral Research 14, pp. 345-356 (Dec. 1990).
	Franchetti, P. et al. "Synthesis and Evaluation of the Anti-HIV Activity of Aza and Deaza Analogues of IsoddA and Their Phosphates as Prodrugs", J. Med. Chem., Vol. 37, 3534-3541 (1994).
	Gao, W. et al. "Divergent Anti-human Immunodeficiency Virus Activity and Anabolic Phosphorylation of 2',3'-Dideoxynucleoside Analogs in Resting and Activated Human Cells", The Journal of Biological Chemistry, Vol. 269, No. 17, pp. 12633-12638 (April 29, 1994).

Continued on next page.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12152.15USC6	Application Number: 10/726,073
	Applicant: Ucken et al.	Confirmation No.: 2559
	Filing Date: December 1, 2003	Group Art Unit:

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) continued...**

		Harris, S. et al. "Synthesis and Antiviral Evaluation of Phosphoramidate Derivatives of (E)-5-(2-bromovinyl)-2'-deoxyuridine", Antiviral Chemistry & Chemotherapy, Vol. 12, pp. 293-300 (2002).
		Hasegawa, T. et al. "Prodrugs of 2',3'-Didehydro-3'-deoxythymidine", Journal of Pharmaceutical Sciences, Vol. 82, No 12, 1232-1236 (December 1993).
		Knaggs, M. et al. "A QSAR Study Investigating the Effect of L-Alanine Ester Variation on the Anti-HIV Activity of Some Phosphoramidate Derivatives of d4T", Bioorganic & Medicinal Chemistry Letters Vol. 10, pp. 2075-2078 (2000).
		McGuigan, C. et al. "Certain Phosphoramidate Derivatives of dideoxy uridine (ddU) are Active Against HIV and Successfully By-pass Thymidine Kinase", FEBS Letters Vol. 351, pp. 11-14 (1994).
		McGuigan, C. et al. "Lactate Cannot Substitute for Alanine in d4T-Based Anti-HIV Nucleotide Prodrugs - Despite Efficient Esterase-Mediated Hydrolysis" Bioorganic & Medicinal Chemistry Letters Vol. 8, pp. 2949-2954 (1998).
		McGuigan, C. et al. "Synthesis and Anti-HIV Activity of some Haloalkyl Phosphoramidate Derivatives of 3'-azido-3'-deoxythymidine (AZT): Potent Activity of the Trichloroethyl Methoxyalaninyl Compound", Antiviral Research, Vol. 15, pp. 255-263 (1991).
		McGuigan, C. et al. "Synthesis and Anti-HIV Activity of some Novel Chain-Extended Phosphoramidate Derivatives of d4T (stavudine): Esterase Hydrolysis as a Rapid Predictive Test for Antiviral Potency", Antiviral Chemistry and Chemotherapy Vol. 9, pp. 109-115 (1998).
		McGuigan, C. et al. "Synthesis and Anti-HIV Activity of some Novel Lactyl and Glycolyl Phosphate Derivatives", Antiviral Research, Vol. 17, pp. 197-212 (1992).
		McGuigan, C. et al. "Synthesis, Anti-Human Immunodeficiency Virus Activity and Esterase Lability of some Novel Carboxylic Ester-Modified Phosphoramidate Derivatives of Stavudine (d4T)", Antiviral Chemistry & Chemotherapy Vol. 9, pp. 473-479 (1998).
		Mullah, K. et al. "Potential Prodrug Derivatives of 2',3'-Didehydro-2',3'-dideoxynucleosides. Preparations and Antiviral Activities", J. Med. Chem. Vol. 35, No. 15, pp. 2728-2735 (1992).
		Saboulard, D. et al. "Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of Stavudine and Zidovudine", Molecular Pharmacology, Vol. 56, pp. 693-704 (1999).
		Siccardi, D. et al. "Stereoselective and Concentration-Dependent polarized Epithelial Permeability of a Series of Phosphoramidate Triester Prodrugs of d4T: An in Vitro Study in Caco-2 and Madin-Darby Canine Kidney Cell Monolayers", The Journal of Pharmacology and Experimental Therapeutics, Vol. 307, No. 3, pp. 1112-1119 (2003).
		Siccardi, D. et al. "Stereospecific Chemical and Enzymatic Stability of Phosphoramidate Triester Prodrugs of d4T in Vitro", European Journal of Pharmaceutical Sciences Vol. 22, pp. 25-31 (2004).
		Siddiqui, A. et al. "Enhancing the Aqueous Solubility of d4T-Based Phosphoramidate Prodrugs", Bioorganic & Medicinal Chemistry Letters Vol. 10, pp. 381-384 (2000).
		Tortolani, D. et al. "Prodrugs of 2',3'-Didehydro-3'-deoxythymidine (D4T): Synthesis, Antiviral Activity, and Rapid Pharmacokinetic Evaluation", Journal of Pharmaceutical Sciences, Vol. 83, No. 3, pp. 339-343 (1994).

Continued on next page.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 12152.15USC6	Application Number: 10/726,073
	Applicant: Ucken et al.	Confirmation No.: 2559
	Filing Date: December 1, 2003	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) <i>continued...</i>		
		Venkatachalam, T. et al. " <i>Lipase-mediated Stereoselective Hydrolysis of Stampidine and Other Phosphoramidate Derivatives of Stavudine</i> ", Bioorganic & Medicinal Chemistry Vol. 12, pp. 3371-3381 (2004).
		Venkatachalam, T. et al. " <i>Stereochemical Influence on Lipase-Mediated Hydrolysis and Biological Activity of Stampidine and Other Stavudine Phosphoramidates</i> ", Bioorganic & Medicinal Chemistry, Vol. 13, pp. 1763-1773 (2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	